Zoetis Inc. $ZTS Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 42,306,764 shares of the company’s stock after buying an additional 419,777 shares during the quarter. Vanguard Group Inc. owned approximately 9.55% of Zoetis worth $6,190,326,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. Brighton Jones LLC lifted its holdings in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares in the last quarter. Empowered Funds LLC lifted its stake in Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after buying an additional 657 shares in the last quarter. Intech Investment Management LLC lifted its stake in Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after buying an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after buying an additional 1,422 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Zoetis during the second quarter worth $11,104,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.8%

NYSE ZTS opened at $126.64 on Tuesday. The firm has a market capitalization of $53.46 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 2.12 and a beta of 0.96. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00. The company’s 50 day moving average price is $124.59 and its 200 day moving average price is $135.21.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio is presently 35.22%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. BTIG Research reissued a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research report on Wednesday, December 3rd. Bank of America upped their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday. Barclays assumed coverage on shares of Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price for the company. Finally, Piper Sandler reissued a “neutral” rating and set a $135.00 price target (down previously from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.